Advertisement
Correspondence| Volume 70, ISSUE 1, e1-e2, July 01, 2011

Hippocampal Glutamate Levels and Striatal Dopamine D2/3 Receptor Occupancy in Subjects at Ultra High Risk of Psychosis

Published:April 11, 2011DOI:https://doi.org/10.1016/j.biopsych.2010.11.030
Hippocampal Glutamate Levels and Striatal Dopamine D2/3 Receptor Occupancy in Subjects at Ultra High Risk of Psychosis
Previous ArticleBimodal Distribution of Polyunsaturated Fatty Acids in Schizophrenia Suggests Two Endophenotypes of the Disorder
Next ArticleReply to: Hippocampal Glutamate Levels and Striatal Dopamine D2/3 Receptor Occupancy in Subjects at Ultra High Risk of Psychosis
      With great interest we read the recent article, “Altered Relationship Between Hippocampal Glutamate Levels and Striatal Dopamine Function in Subjects at Ultra High Risk of Psychosis” (
      • Stone J.M.
      • Howes O.D.
      • Egerton A.
      • Kambeitz J.
      • Allen P.
      • Lythgoe D.J.
      • et al.
      Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.
      Biol Psychiatry. 2010; 68: 599-602
      ). This study reported a negative relation between left hippocampal glutamate levels and presynaptic fluorine-18-L-dihydroxyphenylalanine ([18F]DOPA) uptake in the left striatum of patients with an at-risk mental state (ARMS, also referred to as ultra high risk [UHR] for psychosis) but not in healthy controls. Additionally, the authors found evidence that this relationship may predict later transition to psychosis. These results are an important step in unraveling the etiology of psychosis and schizophrenia and may point to the possibility for a glutamatergic pharmacologic intervention to decrease the risk of transition to psychosis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Stone J.M.
        • Howes O.D.
        • Egerton A.
        • Kambeitz J.
        • Allen P.
        • Lythgoe D.J.
        • et al.
        Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.
        Biol Psychiatry. 2010; 68: 599-602
        View in Article
        • Carlsson A.
        • Waters N.
        • Holm-Waters S.
        • Tedroff J.
        • Nilsson M.
        • Carlsson M.L.
        Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence.
        Annu Rev Pharmacol Toxicol. 2001; 41: 237-260
        View in Article
        • Lisman J.E.
        • Coyle J.T.
        • Green R.W.
        • Javitt D.C.
        • Benes F.M.
        • Heckers S.
        • Grace A.A.
        Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.
        Trends Neurosci. 2008; 31: 234-242
        View in Article
        • Lodge D.J.
        • Grace A.A.
        The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation.
        Neuropsychopharmacology. 2006; 31: 1356-1361
        View in Article
        • Stone J.M.
        • Morrison P.D.
        • Pilowsky L.S.
        Glutamate and dopamine dysregulation in schizophrenia—A synthesis and selective review.
        Psychopharmacologie. 2007; 21: 440-452
        View in Article
        • Innis R.B.
        • Cunningham V.J.
        • Delforge J.
        • Fujita M.
        • Gjedde A.
        • Gunn R.N.
        • et al.
        Consensus nomenclature for in vivo imaging of reversibly binding radioligands.
        J Cereb Blood Flow Metab. 2007; 27: 1533-1539
        View in Article
        • Abi-Dargham A.
        • Rodenhiser J.
        • Printz D.
        • Zea-Ponce Y.
        • Gil R.
        • Kegeles L.S.
        • et al.
        Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.
        Proc Natl Acad Sci U S A. 2000; 97: 8104-8109
        View in Article
        • Abi-Dargham A.
        • van de Giessen E.
        • Slifstein M.
        • Kegeles L.S.
        • Laruelle M.
        Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects.
        Biol Psychiatry. 2009; 65: 1091-1093
        View in Article
        • Bloemen O.J.
        • de Koning M.B.
        • Gleich T.
        • Meijer J.
        • Boot E.
        • Booij J.
        • et al.
        Striatal D2 receptor binding in subjects at Ultra High Risk for psychosis.
        in: Presented at the Early Psychosis Association Conference, Amsterdam2010 (November 2010)
        View in Article
        • Stone J.M.
        • Day F.
        • Tsagaraki H.
        • Valli I.
        • McLean M.A.
        • Lythgoe D.J.
        • et al.
        Glutamate dysfunction in people with prodromal symptoms of psychosis: Relationship to gray matter volume.
        Biol Psychiatry. 2009; 66: 533-539
        View in Article
        • Booij J.
        • Tissingh G.
        • Boer G.J.
        • Speelman J.D.
        • Stoof J.C.
        • Janssen A.G.
        • et al.
        [123 I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson;s disease.
        J Neurol Neurosurg Psychiatry. 1997; 62: 133-140
        View in Article
        • Voruganti L.
        • Slomka P.
        • Zabel P.
        • Costa G.
        • So A.
        • Mattar A.
        • Awad A.G.
        Subjective effects of AMPT-induced dopamine depletion in schizophrenia: Correlation between dysphoric responses and striatal d(2) binding ratios on SPECT imaging.
        Neuropsychopharmacology. 2001; 25: 642-650
        View in Article
        • Boot E.
        • Booij J.
        • Hasler G.
        • Zinkstok J.R.
        • de H.L.
        • Linszen D.H.
        • et al.
        AMPT-induced monoamine depletion in humans: Evaluation of two alternative [123I]IBZM SPECT procedures.
        Eur J Nucl Med Mol Imaging. 2008; 35: 1350-1356
        View in Article
        • Lutkenhoff E.S.
        • van Erp T.G.
        • Thomas M.A.
        • Therman S.
        • Manninen M.
        • Huttunen M.O.
        • et al.
        Proton MRS in twin pairs discordant for schizophrenia.
        Mol Psychiatry. 2010; 15: 308-318
        View in Article
        • Tsai G.E.
        • Lin P.Y.
        Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
        Curr Pharm Des. 2010; 16: 522-537
        View in Article
        • Valli I.
        • Stone J.
        • Mechelli A.
        • Bhattacharyya S.
        • Raffin M.
        • Allen P.
        • et al.
        altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis.
        Biol Psychiatry. 2010; 69: 97-99
        View in Article

      Article info

      Publication history

      Published online: April 11, 2011

      Footnotes

      All authors reported no biomedical financial interests or potential conflicts of interest.

      Please also see associated correspondence, doi 10.1016/j.biopsych.2011.01.039.

      Identification

      DOI: https://doi.org/10.1016/j.biopsych.2010.11.030

      Copyright

      © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      Linked Article

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX